Caracciolo et al.[148] elegantly explained how MYC contributes to genomic instability, switching the preferential DNA repair mechanisms to the error-prone PARP-mediated alternative non-homologous end joining, and pointed to its potential use as a predictive biomarker for PARPi treatments in MM[148]. The gene discussed is MYC; the disease is Miyoshi myopathy.